
Metastatic colorectal cancer trial launches in the US
A Phase II trial to investigate onvansertib for the second line treatment of patients with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) has treated its first patients. The ONSEMBLE trial is designed to demonstrate a clinically meaningful difference in response and onvansertib’s contribution to standard of care (SoC)… Read More















